Favipiravir is a Small Molecule owned by FUJIFILM Toyama Chemical, and is involved in 47 clinical trials, of which 36 were completed, 10 are ongoing, and 1 is planned.

Favipiravir is a viral RNA polymerase inhibitor that inhibits viral replication within cells to prevent viral propagation. Favipiravir is clearly-characterized by the mechanism of action that is different from the existing anti-influenza viral drugs. By host cellular enzymes, favipiravir is converted to the active form, ribofuranosyl triphosphate (T-705RTP), and T-705RTP selectively and directly inhibits the viral replication enzyme, RNA dependent RNA polymerase. In addition, favipiravir shows antiviral activity against resistant viruses to existing drugs due to the different mechanism of action.

The revenue for Favipiravir is expected to reach a total of $696m through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Favipiravir NPV Report.

Favipiravir is originated and owned by FUJIFILM Toyama Chemical. Appili Therapeutics is the other company associated in development or marketing of Favipiravir.

Favipiravir Overview

Favipiravir (Avigan) is an antiviral agent. It is formulated as tablets for oral route of administration. It is indicated for the new or reemerging influenza influenza virus infections (limited to cases in which other anti-influenza virus drugs are ineffective or not sufficiently effective) and for the treatment of patients with mild to moderate COVID-19 disease.

Favipiravir is under development for the treatment of severe fever thrombocytopenia syndrome, influenza A and B virus infections in the US, severe fever with thrombocytopenia syndrome and coronavirus Disease 2019 (COVID-19) in Japan and Lassa fever.

It was under development for the treatment of Ebola virus infections and chikungunya fever.

Appili Therapeutics Overview

Appili Therapeutics is a bio-pharmaceutical company. The company involved in developing and commercializing anti-infective drugs for the treatment of infectious diseases and drug-resistant pathogens. Its pipeline products include ATI-1501, an oral suspension antibiotic liquid reformulation paired with metronidazole used for treating parasitic and anaerobic bacterial infections, including Clostridium difficile; ATI-1503, is focused on generating negamycin analogue candidates, against gram-negative pathogens including bacterial threats such as Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and carbapenem-resistant Enterobacteriaceae (CRE); ATI-1701, a vaccine that work against the bacteria Francisella tularensis. The company works in collaboration with science and industry partners, governments, and government agencies for in-licensing opportunities. Appili Therapeutics is headquartered in Halifax, Nova Scotia, Canada.

The company reported revenues of (Canadian Dollars) CAD1.4 million for the fiscal year ended March 2022 (FY2022). The operating loss of the company was CAD24.6 million in FY2022, compared to an operating loss of CAD15.7 million in FY2021. The net loss of the company was CAD25.1 million in FY2022, compared to a net loss of CAD14.3 million in FY2021.

Quick View – Favipiravir

Report Segments
  • Innovator (NME)
Drug Name
  • Favipiravir
Administration Pathway
  • Oral
Therapeutic Areas
  • Hematological Disorders
  • Infectious Disease
Key Companies
Highest Development Stage
  • Marketed

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.